Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 12/20 | 0.63 |
| ▸ | PTGER2 | P43116 | 11/20 | 0.63 |
| ▸ | PTGER4 | P35408 | 9/20 | 0.63 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | PTGFR | P43088 | 3/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.56 |
| ▸ | PTGIR | P43119 | 2/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | TNKS | O95271 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309761 | 1.00 | PTGER3 (0.63) | PTGER3PTGER2PTGER4PTGDRTBXA2R | |
| SCHEMBL1150939 | 1.00 | PTGER3 (0.63) | PTGER3PTGER2PTGER4PTGDRTBXA2R | |
| Methacrylic Acid SCHEMBL10714797 | 0.90 | PTGER3 (0.54) | PTGER3PTGER2PTGER4PTGDRTBXA2R | |
| SCHEMBL5007834 | 0.89 | PTGER3 (0.52) | PTGER3PTGER2PTGER4PTGDRTBXA2R | |
| SCHEMBL7134072 | 0.87 | EGFR (0.57) | PTGER3PTGER2PTGER4PTGDRTBXA2R | |
| SCHEMBL28893816 | 0.87 | PTGER3 (0.58) | PTGER3PTGER2PTGER4PTGDRTBXA2R | |
| SCHEMBL3256824 | 0.87 | PTGER3 (0.58) | PTGER3PTGER2PTGER4PTGDRTBXA2R | |
| SCHEMBL7499883 | 0.86 | NFKB1 (0.60) | PTGER3PTGER2PTGER4PTGDRTBXA2R | |
| SCHEMBL5873000 | 0.86 | CA1 (0.53) | PTGER3PTGER2PTGER4PTGDRTBXA2R | |
| SCHEMBL12075162 | 0.85 | LMNA (0.61) | PTGER3PTGER2PTGER4PTGDRTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8279435-B2 | Nanostructured metal-polyaniline composites and applications thereof | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2012-10-02 | — | — | US | disclosed |
| US-7786037-B2 | Silver, gold, platinum, palladium; porous asymmetric membrane; acidic dopant of hydrochloric acid, phosphoric acid, citric acid, madelic acid, trifluoroacetic acid, para-toluenesulfonic; metal salt has reduction potential greater than polyaniline; easily recovered, reused hydrogenation catalyst | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100060894-A1 | NANOSTRUCTURED METAL-POLYANILINE COMPOSITES AND APPLICATIONS THEREOF | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2010-03-11 | — | — | US | disclosed |
| US-20080171656-A1 | Nanostructured metal-polyaniline composites | ENERGY, U.S. DEPARTMENT OF | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100060894-A1 | NANOSTRUCTURED METAL-POLYANILINE COMPOSITES AND APPLICATIONS THEREOF | PARG, PARN, FHIT | PTGER3 3806/4885PTGER2 4206/4885PTGER4 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.